1/1
2 files

Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study. Supplementary figures and table.

figure
posted on 24.01.2022, 10:25 authored by Jeff P Sharman, Robert M. Rifkin, Carol F. Kirchhoff

Supplemental Table S1. Summary of safety findings from REFLECTIONS B328-06 study [2]. (© The Author(s) 2019. https://creativecommons.org/licenses/by-nc/4.0/)

Supplemental Figure S1. CD19+ B-cell count over time following treatment with RTX-PF, RTX-EU, and RTX-US in patients with RA [1].

Supplemental Figure S2. Study design (REFLECTIONS B328-06) [2]. (© The Author(s). https://creativecommons.org/licenses/by-nc/4.0/)

Supplemental Figure S3. Incidence of anti-drug antibodies (safety population). Created using data from [2].


Funding

Merck

History